Ranbaxy Pharmaceuticals Inc (RPI), a wholly-owned subsidiary of Ranbaxy Laboratories Limited (Ranbaxy), has launched the authorised generic cevimeline hydrochloride 30 mg. capsules in the US market, under an agreement with Daiichi Sankyo.
Cevimeline hydrochloride is indicated for the treatment of symptoms of dry mouth associated with Sjogren’s syndrome, an autoimmune disorder affecting the moisture-producing glands, and is presently distributed by Daiichi Sankyo, under the brand name Evoxac. Evoxac generated total annualised sales of $62.4 million in the US (IMS – MAT June 2012).
Bill Winter, Vice President, Trade Sales and Distribution, North America, Ranbaxy said, “Ranbaxy is pleased to announce the launch of cevimeline hydrochloride in 30 mg. capsules, as the authorised generic of Evoxac in the US. This launch further underscores Ranbaxy’s resolve to bring high quality, affordable generic medicines to the US healthcare system to meet the growing needs of patients and prescribers.”
Regarding the launch, Arun Sawhney, CEO and Managing Director, Ranbaxy, said, “We welcome the opportunity to launch cevimeline hydrochloride in the US market. This authorised generic form of Evoxac is an excellent example of optimising operational synergies that exists between Ranbaxy and Daiichi Sankyo, while accelerating our global business efforts. We see a continuing opportunity to leverage our combined strengths of innovation and the manufacture and marketing of affordable, high quality, generic medicines through this collaboration.”
Commenting on the launch of an authorised generic of Evoxac, Dr Tsutomu Une, Chairman, Ranbaxy, said, “We refer to the strategy of optimising the diverse assets of both companies as our hybrid business model, that will allow both organisations to effectively seize opportunities across the full pharmaceutical value chain and product life-cycle, by leveraging the R&D and manufacturing of both Daiichi Sankyo and Ranbaxy. As such, we will continue to reinforce our respective business platforms over the longer term through this hybrid strategy.”
EP News Bureau
- Advertisement -
